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Abstract. Whether administration of folic acid to children with malaria anemia is helpful is controversial. Therefore,
we conducted a randomised, placebo-controlled trial of 14 days of treatment with folic acid (1 mg/d) in Zambian children
with malaria anemia treated with either sulfadoxine/pyrimethamine (SP) or atovaquone/proguanil (AP). Among chil-
dren who received SP, the prevalence of parasitemia was higher in children treated with folic acid than among those
given placebo at days 3, 7, and 14 after the start of treatment, and the difference at day 3 was statistically significant
(P 0.013). Folic acid treatment had no effect on parasitemia in children treated with AP. Administration of folic acid
led to a small increase in packed cell volume over that seen in the placebo group at days 14 and 28 after the start of
treatment.
INTRODUCTION
Anemia is a serious complication of Plasmodium falci-
parum infection and a major cause of morbidity and mortality
in young Zambian children.1 The pathogenesis of malarial
anemia is complex, but red cell destruction, either directly by
the parasite or as a result of an immune attack, is considered
to be the major cause. However, underlying iron and/or folic
acid deficiencies may be aggravating factors. Treatment of
malarial anemia requires an effective anti-malarial drug to
eliminate parasitemia, but supportive therapies such as hema-
tinics and blood transfusion may also be needed to enhance
hematological recovery. The high prevalence of HIV infec-
tion in Zambia increases the risk of blood transfusion.
Recent studies have provided some evidence in favor of
iron supplementation after anti-malarial treatment of chil-
dren with malaria anemia,2 but the value of treatment with
folic acid remains controversial.3 It has been suggested that,
in the presence of a poor dietary intake of folic acid, the rapid
erythroid hyperplasia that occurs after hemolysis can cause
depletion of folate stores, which may, in turn, lead to delayed
hematological recovery.4 However, some studies have shown
that folate deficiency is uncommon in African children with
malarial anemia,5 and folate supplementation may not be
necessary for their hematological recovery.
Sulfadoxine/pyrimethamine (SP) is still the first line treat-
ment of uncomplicated malaria in many parts of Africa, al-
though this situation is changing. Concern has been expressed
that co-administration of folic acid with SP could antagonize
the anti-parasitic activity of this drug. Exogenous folate can
antagonize anti-folate anti-malarial drugs such as SP and
proguanil in vitro,6 and it has been suggested that high red cell
folate concentrations favor parasite growth7 and that folate
deficiency may be protective.8 Three previous studies in Af-
rican children give some support to the view that the efficacy
of SP my be compromised by the co-administration of folic
acid. In The Gambia, folic acid given to children with uncom-
plicated malaria at a dose of 5 mg/d for 28 days had a signifi-
cant effect on the parasitological response to treatment with
SP.9 In Kenya, patients with uncomplicated malaria (mean
age, 80 months) were treated with SP and iron and allocated
randomly to receive folic acid (2.5 or 5 mg according to age)
or not for 30 days. Survival analysis showed delayed parasite
clearance in the patients who received folic acid, which was
most marked in the first week after the start of treatment, but
no effect on clinical recovery.10 In Malawi, children with un-
complicated falciparum malaria who failed treatment with SP
had a small, but significantly higher, mean blood folate con-
centration than children who had an adequate clinical and
parasitological recovery.11
Before the start of this trial, folic acid was given routinely
to children with malarial anemia seen at Macha Mission Hos-
pital, Zambia, but the staff was uncertain of its benefit. To
determine this, we undertook a randomized, placebo-
controlled trial of treatment with folic acid in children with
moderate to severe malarial anemia (SMA). Patients in the
trial were randomized to receive SP or atovaquone/proguanil
(AP), using a factorial design. The results of the comparison
in the efficacies of SP and AP in the treatment of malaria
anemia will be presented elsewhere (Mulenga M, Malunga P,
Bennett S, Thuma P, Shulman C, Fielding K, Alloueche A,
Greenwood B, unpublished data). This trial was undertaken
to help the Malarone Donation Program decide how to use
most effectively the one million doses of AP offered for use in
Africa by GlaxoSmithKline. This proved to be difficult to do,
and the donation policy has not been pursued.
MATERIALS AND METHODS
Study design. The study compared children with moderate
to severe malaria anemia treated with SP or AP and folic acid
or placebo using a factorial design. The study protocol was
approved by the Tropical Diseases Research Center, Ndola,
and the London School of Hygiene and Tropical Medicine
Ethics Committees. The study was monitored by an indepen-
dent Data and Safety Monitoring Board (DSMB).
Study site and duration. The study was carried out in the
40-bed pediatric ward at Macha Mission Hospital (MMH),
located in the southern province of Zambia. Malaria trans-
mission in the area is seasonal, occurring between December
and May. Children were recruited in two consecutive malaria
transmission seasons: December 2000 to June 2001 (Phase 1)
and February to June 2002 (Phase 2).
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Study subjects. Children 6–119 months of age who pre-
sented to the outpatient department were eligible for enroll-
ment if they met the following inclusion criteria: a blood film
positive for asexual forms of P. falciparum at a density of
50–500,000 parasites/L; the presence of fever ( 37.5°C) or
a history of fever in the preceding 24 hours; a packed cell
volume (PCV) of 9–21%; a body weight of 5 kg or greater.
After review by the DSMB during the course of the trial, the
PCV cut-off was raised from 9% to 12%. Exclusion criteria
were an inability to take oral medication; an inability to sit or
stand unsupported; respiratory distress or other symptoms
and signs of severe malaria as defined by the World Health
Organization (WHO),12 with the exception of anemia or hy-
perparasitemia; serious concurrent illnesses such as severe
malnutrition or tuberculosis; receipt of an anti-malarial other
than chloroquine in the previous 2 weeks; an allergy to anti-
folates; receipt of folic acid in the previous week; and blood
transfusion in the previous month.
Sample size. It was assumed that the treatment failure rate
within 14 days of the start of treatment in children who re-
ceived SP or AP would be about 10%. It was hypothesized
that co-administration of folic acid would increase this to
20%. To detect this difference with a one-sided, type 1 error
of 0.05 (it was considered highly improbable that folic acid
would increase the efficacy of SP or AP) and 80% power, 305
children were required in each study arm.
Randomization. Before the start of the trial, a computer-
generated randomization list was prepared by the DSMB’s
statistician to assign treatments in equal numbers (in blocks of
16) to either AP or SP with or without folic acid supplemen-
tation. Folic acid or placebo was given only to children who
had a PCV greater than 15%, because of concern over a
possible, serious adverse interaction between SP and folate in
severely anemic children. All drugs were individually ran-
domized and pre-packed by two people unconnected with the
trial. The DSMB’s statistician kept one copy of the random-
ization code and the senior hospital pharmacist kept the other
copy at the study site.
Study drugs and dose. Study children were admitted to the
hospital for 3 days and received, under supervision, either AP
(Malarone; GlaxoSmithKline, Brentford, UK) at a dose of
approximately 17 mg atovaquone/7 mg proguanil/kg orally
once daily for 3 days or SP (Cosmos Pharmaceuticals, Nairo-
bi, Kenya) at a dose of approximately 25 mg/kg sulfadoxine
on one occasion. The solubility and drug content of the SP
tablets was validated by high performance liquid chromatog-
raphy. Folic acid (Cosmos Pharmaceuticals) was administered
as a 1-mg tablet given once daily for 14 days, the first four
doses under supervision. Concomitant medications, such as
paracetamol for fever, were documented. However, children
who needed treatment with anti-microbial agents known to
have anti-malarial properties were excluded. Any patient
with clinical or parasitological failure or who was judged by
the clinician in charge to be developing danger signs of com-
plicated malaria was given quinine in an initial dose of 20
mg/kg intravenously or 10 mg/kg orally, depending on their
clinical condition. Oral quinine was continued at a dose of 10
mg /kg every 8 hours for a further 6 days. Patients received
blood transfusion if their PCV fell below 9%, regardless of
clinical status, if they developed respiratory distress, or if they
developed extreme lethargy or were not improving.
On discharge, parents were given sufficient folic acid tab-
lets or placebo for a further 10 days of treatment, and parents
were instructed to give the tablets to children at home.
Clinical management. Children were managed according to
the WHO guidelines for treatment of complicated malaria. A
clinician assessed symptoms once daily or more frequently if
the patient was very ill, and vital signs were measured every
4 hours. A clinician determined the prevalence and severity of
any adverse events (AEs) that occurred during admission or
follow-up. Patients were discharged on the third day provided
that they had normal vital signs and were able to take oral
medication. After discharge, children were followed up at
home on days 7, 14, and 28. At each visit, a study clinician
assessed the child’s recent symptoms, recorded any medica-
tions taken since discharge, and carried out a physical exami-
nation. A clinical officer followed up absentee children at the
home the same day or the next day.
Laboratory investigations. All laboratory investigations
were carried out without knowledge of the patient’s treat-
ment group. At days 0, 3, 7, 14, 21, and 28, blood smears for
parasite counts were prepared, stained for 15 minutes in 10%
Giemsa stain, and examined by two experienced microsco-
pists working independently. Parasites were counted against
200 white blood cells, and parasite density was calculated on
the basis of measured white cell count. A blood smear was
declared negative if no parasites were seen after examination
of 100 high power fields. If the parasite density showed a
difference of one logarithm or greater between readers, M.M.
adjudicated the final result. MSP2 typing was used to differ-
entiate re-infections from recrudescences.13
PCV was measured at days 0, 3, 7, 14, and 28 after the start
of study treatment. At days 0, 14, and 28, a full blood count
was done using an automated counter (Cobas-Micros; Hoff-
mann-La Roche, Basel, Switzerland). A reticulocyte index
was determined on fresh blood samples obtained on days 0
and 14. Blood glucose concentrations were measured using a
glucometer (Glucotrend; Hoffmann-La Roche) before study
drug intake and at anytime during the study if hypoglycemia
was suspected. At days 0 and 14, serum specimens were col-
lected, stored at −20°C, and at the end of the study, trans-
ported to the Human Nutrition Research Laboratories of the
Medical Research Council, Cambridge, UK, where folate
concentrations were analyzed using the IMx system folate
assay (Abbott Laboratories, Abbott Park, IL).
Trial endpoints. The primary trial endpoint was treatment
failure, defined as the occurrence of any one of the following
within 14 days of the start of treatment: a need for escape
medication (quinine); a need for blood transfusion; failure to
increase PCV to greater than 21%; or death. Additional end-
points were the presence or absence of parasitemia at days 3,
7, 14, and 28 after the start of treatment, the mean PCV at
days 7, 14, and 28 after treatment, the mean corpuscular vol-
ume (MCV) 7 and 14 days after treatment, and the mean
reticulocyte count 14 days after the start of treatment. AEs
were defined as any symptoms or signs that developed or
increased in severity after treatment within a period of 7 days
of the initiation of trial treatment. However, serious AEs
were monitored up to day 28.
Statistical methods. Data were double-entered, validated
(EPI-INFO version 6.04b; CDC), and analyzed using STATA
version 7. Primary outcomes were analyzed by intent-to-treat.
Thus, all children who received the first dose of study medi-
cation were analyzed. 2 test or Fisher exact test, or multi-
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variate analyses by unconditional logistic regression, were
used to compare binary outcomes such as treatment failure.
The likelihood ratio test was used to compare different mul-
tivariate models. Means of continuous outcomes such as PCV
and parasite density were compared using the Student t test
and multiple regression analysis, following normalization
when necessary. Mann-Whitney U test was used to compare
continuous outcomes that were not normally distributed such
as serum folate concentrations.
An analytical plan was prepared before the randomization
code was broken. An initial analysis studied whether there
was any interaction between the two arms of the trial, the
comparison between two anti-malarials, and that between
folic acid treatment and placebo administration. No interac-
tion was found; therefore, for clarity, the folic acid supple-
mentation and the anti-malarial treatment components of the
trial are being presented in separate papers.
RESULTS
One hundred eighty-three (72%) of the 255 patients
enrolled into the main study who had a PCV greater
than 15% were randomized to receive either folic acid
or placebo. Two additional patients with a PCV of 15%
inadvertently received folic acid and have been included in
the analysis. Forty-seven children were allocated to the folic
acid plus AP group, 45 to the folic acid plus SP group, 47 to
the placebo plus AP group, and 46 to the placebo plus SP
group. The distribution of baseline characteristics among chil-
dren in the folic acid and placebo groups was similar (Ta-
ble 1).
Treatment failure. Eighteen patients failed treatment: 7
(8%) in the folic acid group and 11 (12%) in the placebo
group. The effect of folic acid supplementation on treatment
failure was not significant (odds ratio [OR]: 0.62; 95% confi-
dence interval [CI]: 0.19, 1.86; P  0.35). Treatment failures
were distributed as follows: three patients in the folic acid
group and four in the placebo group received escape medi-
cation, two patients in the folic acid group and four in the
placebo group received a blood transfusion, and one patient
in the folic acid group and two patients in the placebo group
died within 14 days of the start of study treatment. All three
deaths occurred within 48 hours of admission; hypoglycemia
was implicated in two of the deaths. Among patients who
received SP, there were 6 failures among 45 children who
received folic acid and 9 among 46 who received placebo
(P  0.42), whereas among patients who received AP, there
were two failures in each group.
Parasite clearance. The proportions of children in whom
asexual malaria parasites were detected and mean parasite
densities in positive blood smears at days 3, 7, 14, and 28 after
the start of treatment are shown in Table 2. During the first
few days after the start of treatment, more children in the
folate than in the placebo group were parasitemic, and at day
3, the difference between groups was statistically significant
(P < 0.02). Differences between the groups were not apparent
on days 7, 14, or 28. Further analysis showed that, among
children who received folic acid, there was a significant inter-
action between parasitological findings and the anti-malarial
drug used (logistic model, likelihood ratio test P for interac-
tion  0.05). Among children who received AP, there were
no significant differences in parasite prevalence between chil-
dren who received folic acid and those who did not. Thus, at
day 3, the prevalence of parasitemia in children who had
received folic acid was 4/46 compared with 3/45 in those who
had received placebo. Only three children in either group
were parasitemic after day 3. However, among children who
received SP, the prevalence of parasitemia was higher at days
3, 7, and 14 in children who had received folic acid than in
those who had received placebo, and the difference between
groups at day 3 was statistically significant (Table 3). No sig-
nificant differences in the number of patients with gameto-
cytes were observed between groups on any day of follow-up
(data not shown).
Hematological indexes and serum folate measure-
ments. Hematological indexes were analyzed according to
supplementation group using multiple regression models that
controlled for baseline values (Table 4). At days 14 and 28,
the mean PCV was higher in the folic acid supplementation
group than in the placebo group; the difference was statisti-
cally significant (P 0.02) at day 14. No other differences in
hematological indexes were detected between the two treat-
ment groups.
Serum folate concentrations were measured in a randomly
selected sample of 20 children in the placebo group and
49 children in the folic acid group. At baseline, the me-
dian serum folate concentrations were similar: 13.8 ng/mL
(range, 7.5–56.1 ng/mL) in the folic acid group and 15.0 ng/mL
(range, 4.5–61.0 ng/mL) in the placebo group. At day 14,
the median was higher among children who had received
folic acid (17.7 ng/mL; range, 9.1–46.8 ng/mL) than in child-
ren who had received placebo (13.4 ng/mL; range, 5.4–
18.7 ng/mL). No serum folate levels were below the lower
bound of normal (< 2.5 ng/mL) in any child at baseline or at
day 14.
Adverse events. Six serious AEs (SAEs), including two
deaths, occurred in children who had received folic acid, and
10 SAEs with three deaths in children who had received pla-
cebo (P  0.32). In addition to the three early deaths con-
sidered in the section on treatment failures, there was one late
death from marasmus and pneumonia in a child who had
received folic acid and one from the complications of measles
in a child who had received placebo. SAEs were mainly hos-
pital admissions with an acute infection such as measles or
pneumonia; none were thought to be drug related. Non-
serious AEs and other clinical features assessed at days 7, 14,
TABLE 1
Baseline variables in the folic acid treatment and placebo groups
Baseline characteristics
Folic acid
(n  92)
Placebo
(n  93)
Antipyretic intake last 24 hours % (n) 68 (62) 63 (59)
Sex: female % (n) 52 (47) 52 (48)
Breast-fed (%) 51 (46) 56 (52)
Dill-Glazko test positive % (n) 65 (43/66) 56 (40/71)
Referral from Health Centre % (n) 44 (40) 43 (40)
Traditional medication % (n) 38 (35) 41 (38)
Bed net use % (n) 10 (9) 8% (7)
Hookworm ova % (n) 4 (2/53) 0 (0/53)
Packed cell volume (%) [mean (SD)] 18.2 (1.4) 18.0 (1.3)
White cell count ×109/L [mean (SD)] 11.1 (5.8) 11.3 (5.7)
Mean corpuscular volume (fl)
[mean (SD)]
78.9 (10.6) 79.5 (11.7)
Reticulocyte index [mean (SD)] 1.7 (1.5) 1.8 (1.5)
Where n is different, the denominator is also shown in parenthesis (n/N).
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and 28 were comparable in the two study groups (data not
shown).
DISCUSSION
To treat malarial anemia, effective drugs are needed that
will rapidly eliminate the malaria parasite, and hematinics
such as folate and iron may be needed to boost hematological
recovery, thus reducing reliance on blood transfusions.14
There is some evidence to support the use of iron supplemen-
tation2,15 in African children with malaria anemia but little to
support treatment with folic acid, although this is frequently
given.
In this study, we found that administration of folic acid in a
dose of 1 mg/d for 14 days to children with malaria anemia
resulted in higher mean PCV values 14 and 28 days after
treatment than seen in children who had received placebo.
Although the differences between groups were only modest
(an increase in PCV of ∼1%), the difference between groups
at day 14 was statistically significant. This effect was seen
despite the fact that initial serum folate levels were within the
normal range in all of the randomly selected sample of chil-
dren who were tested. In a study in Kenya10 in which larger
doses of folic acid were used, no increase in the proportion of
children with a hemoglobin greater than 8 g/dL was seen, but
mean hemoglobin values were not given. This difference may
be caused in part by the fact that subjects in the Kenyan study
were older (average age, 80 months) than those in the current
trial and to the fact that they were also given iron supplemen-
tation.
TABLE 3
Proportions of children treated with SP with parasitemia and parasite
densities by supplementation group at various days of follow-up
Day of
study Folate Placebo
P
value
0 n 45 46
Median parasite
density
33,200 31,700
Range 2,800–366,600 1,400–98,800
3 n/N (%) 11/44 (25%) 1/44 (2%) 0.003
Median parasite
density
1,000 90
Range 100–17,400
7 n/N (%) 3/42 (7%) 0/42 0.12
Median parasite
density
3,600
Range 300–40,900
14 n/N (%) 5/40 (13%) 1/40 (3%) 0.44
Median parasite
density
600 1,500
Range 300–5,200
28 n/N (%) 7/36 (20%) 11/36 (30%) 0.49
Median parasite
density
3,200 4,900
Range 400–3,500 400–62,00
TABLE 4
Mean values for haematological indices and adjusted mean differ-
ences at follow-up by supplementation and group
Measurement
Folate Placebo
Adjusted mean
difference (95% CI)*
P
valuen Mean (SD) n Mean (SD)
Packed cell volume (%)
Day 7 88 21.9 (3.1) 85 21.4 (3.7) 0.2 (−0.8, 1.2) 0.69
Day 14 86 27.8 (3.4) 80 26.4 (3.7) 1.2 (0.2, 2.2) 0.02
Day 28 71 31.5 (3.2) 78 30.6 (3.8) 0.8 (−0.3, 1.9) 0.16
Mean corpuscular volume (fl)
Day 14 72 83.3 (8.4) 73 85.4 (9.5) −2.2 (−5.1, 0.6) 0.12
Day 28 54 83.5 (6.7) 58 81.2 (8.5) 2.6 (0.32, 5.2) 0.08
Reticulocyte index
Day 14 80 3.6 78 3.3 0.1 (−1.6, 1.2) 0.21
* Reticulocyte index data was log-transformed.
TABLE 2
Proportions of patients with parasitemia by treatment group
Day of study Folate Placebo P value*
0 n 91 93
Median parasite density 25,100 31,200
Range 1,300–366,600 1,300–987,600
GM (95% CI) 26,000 (19,600–34,700) 23,200 (18,500–34,400)
1 n/N (%) 80/89 (90%) 78/92 (85%) 0.37
Median parasite density 9,300 8,700
Range 30–285,300 100–1,013,000
GM (95% CI) 8,900 (5,900–13,400) 8,200 (5,500–12,300)
2 n/N (%) 47/89 (53%) 42/89 (47%) 0.55
Median parasite density 900 600
Range 40–87,200 50–46,800
3 n/N (%) 15/90 (17%) 4/89 (4%) 0.013
Median parasite density range 1,000 200
40–17,400 50–900
7 n/N (%) 4/90 (4%) 0/86 (0%) 0.12
Median parasite density Range 2,000 —
70–40,900 —
14 n/N (%)† 5/86 (6%) 2/83 (2%) 0.44
Median parasite density Range 600 1,000
300–5,200 400–1,500
28 n/N (%)‡ 9/71 (13%) 13/74 (16%) 0.49
Median parasite density Range 5,000 2,500
400–34,600 100–6,200
* Based on Fisher exact test.
† Based on msp2 typing all considered to be re-infections.
‡ Based on msp2 typing all considered to be re-infections except for one recrudescence in the folic acid treatment group.
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The results of our trial confirm those of previous studies
that have shown that co-administration of folic acid can com-
promise the efficacy of SP. Differences in the prevalence of
parasitemia between children who had received folic acid and
those who had received placebo were seen on days 3, 7, and
14 after the start of treatment, but only the difference seen on
day 3 was statistically significant. In the Kenyan study, the
inhibitory effect of folic acid was also most marked in the first
week after the start of treatment.10 At day 28, prevalences of
parasitemia had increased in each group and were similar.
Molecular typing suggested that, surprisingly, nearly all of
these late parasitemias were caused by re-infections; only one
unequivocal recrudescence was detected. It is possible that
ability of SP to clear parasites may be more susceptible to the
inhibitory effect of exogenous folate than its prophylactic ef-
fect and, if this is the case, this could explain these findings.
The overall failure rate of SP in the study population was
only modest (8% parasitological failure at day 14), and it is
possible that a more marked inhibitory effect would have
been seen in a population with a higher prevalence of resis-
tant parasites. Folic acid treatment had no impact on parasite
clearance in children treated with AP, although this combi-
nation contains the anti-folate drug proguanil. This supports
the idea that proguanil achieves its synergistic action with
atovaquone through an alternative mechanism from inhibi-
tion of the folate pathway.
A major limitation of this study was the small sample size.
This study was designed to have 305 subjects in each arm, but
this figure could not be reached, largely because of a drought
in Zambia during the study. The sample size was only one
third of that required to detect a 10% difference in failure
rates between the study groups with 95% confidence. Thus,
caution is needed in interpreting our results, but these are
consistent with those of other recent studies.
In conclusion, this study has shown that folic acid treatment
had a modest effect on hematological recovery in children
with malaria anemia and that it had some antagonistic effect
on treatment with SP, but not with AP. Neither effect was
marked but folic acid is probably best avoided, at least in
large doses, when SP is used to treat malaria unless there are
specific indications why it should be used.
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